Nicotinamide Riboside (NR) and NAD+ — A Research Summary

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism and a required substrate for sirtuins and PARP enzymes, which regulate DNA repair, stress responses, and mitochondrial function. NAD+ declines significantly with age — by approximately 50% between middle age and old age in both human and animal studies. This decline impairs mitochondrial function and cellular stress responses.

NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are precursors that efficiently raise cellular NAD+ levels. In aged mice, NAD+ restoration reverses multiple aging phenotypes including cognitive decline, muscle loss, and reduced endurance. The brain is particularly dependent on NAD+ for neuronal energy production and DNA repair.

Human trials consistently show that NR supplementation raises blood NAD+ levels — this is well-established. What is less established is whether this translates to functional benefits. A 2018 phase 1 trial confirmed safety and dose-dependent NAD+ increases in healthy middle-aged adults (Elhassan et al.). Multiple subsequent trials have confirmed NAD+ raising.

For cognitive outcomes specifically, the evidence is thin. A 2021 trial in older adults found some improvements in muscle function but did not show significant cognitive differences. The COGNICET trial (ongoing as of 2026) is examining NR effects on cognitive aging — results are awaited.

The basic science is solid. The human cognitive data is simply not yet there — the question is whether the animal data will translate, not whether the mechanism is real.

Promising. The mechanism is sound, NAD+ raising in humans is confirmed, and the animal evidence for cognitive protection is strong. The gap is human clinical trial data specifically for cognition. Given the safety profile and the strength of the aging biology rationale, this is a reasonable supplement for people interested in longevity biology, with the caveat that cognitive benefits in humans are unproven.

250-1000mg/day of NR in published trials. The most common dose is 300-500mg/day. NMN (nicotinamide mononucleotide) is an alternative precursor with similar mechanism and human trials showing comparable NAD+ increases. The relative clinical benefits of NR vs. NMN remain unsettled.

Good safety profile in trials up to 12 months. Flushing is less common than with niacin. Some users report changes in sleep — likely due to circadian regulation of NAD+ metabolism. Some researchers recommend morning dosing for this reason. Long-term safety beyond 12 months in humans has not been formally studied.

The most intellectually honest position: NR raises NAD+ in humans, NAD+ decline drives aging phenotypes including cognitive decline in animal models, but we do not yet have robust human cognitive trial data. This is a reasonable supplement for people engaged in active longevity management, with the understanding that you are betting on the translation of strong mechanistic and animal evidence before definitive human cognitive trial data exists.